Repare Therapeutics Inc
NASDAQ:RPTX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.75
8.41
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Repare Therapeutics Inc
Repare Therapeutics Inc
Operating Income
Repare Therapeutics Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Operating Income
-$116.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Operating Income
-CA$7.4m
|
CAGR 3-Years
-148%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Operating Income
$9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Operating Income
-$24.9m
|
CAGR 3-Years
46%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-6%
|
|
|
Covalon Technologies Ltd
XTSX:COV
|
Operating Income
-CA$1.4m
|
CAGR 3-Years
48%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Operating Income
-CA$14.1m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-2%
|
|
Repare Therapeutics Inc
Glance View
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 152 full-time employees. The company went IPO on 2020-06-19. The firm is focused on the development of synthetic lethality (SL) based therapies to patients with cancer. The company uses genome wide, SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The firm is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related (ATR) protein kinase for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated (ATM) kinase gene. Its preclinical programs include RP-6306 Protein Kinase Membrane-associated tYrosine- and Threonine- specific cdc-2 inhibitory (PKMYT1)kinase SL inhibitor, in advanced solid tumors.
See Also
What is Repare Therapeutics Inc's Operating Income?
Operating Income
-116.2m
USD
Based on the financial report for Dec 31, 2023, Repare Therapeutics Inc's Operating Income amounts to -116.2m USD.
What is Repare Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-55%
Over the last year, the Operating Income growth was -487%. The average annual Operating Income growth rates for Repare Therapeutics Inc have been -30% over the past three years , -55% over the past five years .
You don't have any saved screeners yet
